Dry skin, itching, and fiery eczema can be caused by allergens, stress, or an overactive immune response.Steroid creams ...

Adults and adolescents treated with icotrokinra experienced improvements in their moderate to severe plaque psoriasis, ...

The IFPA Forum 2025 will unite stakeholders from across the Americas to address the urgent challenges faced by individuals ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Some patients with psoriasis may have a super response to guselkumab, but questions remain regarding the generalizability of treatment strategies.

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Growing up, I watched my mom apply fun lipsticks, powder her face in small compact mirrors, and make sure her lashes were ...

Arcutis is a rare topical dermatology player with accelerating launch metrics and continued growth. Read more about the ...

Higher rates of venous thromboembolism, lymphoma, and infections were observed in those with atopic dermatitis and psoriasis vs control patients.

Celltrion Inc., a major South Korean biopharmaceutical firm, said Thursday it has launched its biosimilar product for Stelara ...